Lmr Partners LLP Affimed N.V. Transaction History

Lmr Partners LLP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.57 - $1.08 $29,275 - $55,469	51,361 New	51,361 $30,000
Q4 2022 Feb 14, 2023	SELL	$1.1 - $2.45 $539,698 - $1.2 Million	-490,635 Reduced 90.52%	51,361 $63,000
Q3 2022 Nov 14, 2022	BUY	$1.96 - $3.32 $49,000 - $83,000	25,000 Added 4.84%	541,996 $1.12 Million
Q2 2022 Aug 15, 2022	BUY	$2.27 - $4.86 $1.11 Million - $2.38 Million	490,635 Added 1861.22%	516,996 $1.43 Million
Q4 2021 Feb 14, 2022	BUY	$5.37 - $7.07 $141,558 - $186,372	26,361 New	26,361 $146,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Lmr Partners LLP with notifications on news.